Immunomedics, Inc. in License Deal with Nycomed - Immunomedics Will Receive Upfront Payment of $40M and Potential Milestones of Up to $580M; Shares Rise

July 14 (Reuters) - Immunomedics Inc said it entered into a licensing agreement with Swiss drug company Nycomed to develop and market veltuzumab, its experimental anti-body for non-cancer indications.